

Mangalam Drugs and Organics Limited

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413



REF: MDOL/CS-SE/2024- 25/038

February 13, 2025

To,

Listing Department
BSE Ltd
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

Scrip Code: 532637

Listing Department
National Stock Exchange of India Limited
“Exchange Plaza”, 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051
Symbol: MANGALAM

Sub: Outcome of the Board Meeting held on Thursday, February 13, 2025

Ref: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) read with SEBI Circular CIR / CFD / CMD / 4 / 2015 dated September 09, 2015

Dear Sir / Madam,

With respect to the captioned subject and mentioned reference, we are pleased to inform that the Board of Directors of the Company, in their meeting held today i.e., Thursday, February 13, 2025 has *inter-alia* transacted, considered and approved the following business:

- The Un-Audited Financial Results (Standalone and Consolidated) along with the Limited Review Report of the Company for the quarter ended December 31, 2024 pursuant to Regulation 33 of the SEBI LODR Regulations. (A copy of the said results, notes thereto and Limited Review Report is annexed hereto and marked as Annexure I.)

Pursuant to Regulation 33(3)(d) of the Listing Regulations, we hereby declare that in respect of the Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2024, the statutory Auditors have not expressed any modified opinion(s) in their Audit Reports.

The Board meeting commenced at 3:00 P.M. and concluded at 6:30 P.M.

We request you to take the same on your records.

Thanking You,

Yours faithfully,
For **Mangalam Drugs & Organics Limited**

Govardhan M. Dhoot
Chairman & Managing Director
DIN: 01240086



Limited Review Report on Unaudited Standalone Financial Results of Mangalam Drugs and Organics Limited for the Quarter ended on 31st December, 2024 and year to date results for the period from 1st April, 2024 to 31st December 2024 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021 as amended.

The Board of Directors,
Mangalam Drugs and Organics Limited,

1. We have reviewed the accompanying statement of unaudited financial results of **Mangalam Drugs and Organics Limited** (the "Company") for the quarter and year to date results for the period from 1st April 2024 to 31st December 2024 (the "Statement") attached herewith, being submitted by the Company, pursuant to the requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Conclusion:

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai
Date: February 13, 2025

For V.S. SOMANI & Co.,
Chartered Accountants
Firm Registration No. 117589W



CA Vidyadhar Somani
Proprietor

Membership No. 102664

UDIN No. 25102664BMITCX9501



MANGALAM DRUGS AND ORGANICS LIMITED
CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2024

| Sr.No | Particulars | Quarter Ended | | | Nine Months Ended | | (Rs. In Lakhs) |
|-----------|------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|-----------------|-------------------|-------------------|-------------------|
| | | 31.12.2024 | 30.09.2024 | 31.12.2023 | 31.12.2024 | 31.12.2023 | Year Ended |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| 1 | Income from Operations | | | | | | |
| | (a) Net Sales and Services from Operations | 8,855.29 | 7,975.17 | 9,704.60 | 24,479.87 | 26,541.58 | 36,735.35 |
| | (b) Other Operating Income | 15.91 | 19.17 | 29.00 | 39.29 | 94.37 | 124.12 |
| | Total Income from Operations (net) (a+b) | 8,871.20 | 7,994.34 | 9,733.60 | 24,519.16 | 26,635.95 | 36,859.47 |
| 2 | Expenses | | | | | | |
| | (a) Cost of Materials Consumed | 4,486.12 | 4,340.21 | 4,664.80 | 12,879.77 | 17,320.54 | 22,475.54 |
| | (b) Purchase of Stock in trade | 371.91 | 234.89 | 198.90 | 1214.08 | 263.33 | 1065.35 |
| | (c) Changes in Inventories of Finished Goods, Work In Progress and Stock-in-trade | 234.93 | (508.72) | 2,062.81 | (893.59) | 1,001.61 | 910.33 |
| | (d) Employee Benefits Expenses | 1,033.75 | 1,017.77 | 897.12 | 3,008.37 | 2,796.48 | 3,907.13 |
| | (e) Depreciation and amortization expenses | 392.76 | 396.75 | 362.39 | 1,176.85 | 1,077.26 | 1,463.22 |
| | (f) Other Expenses(Refer Note No 6) | 1,867.69 | 2,040.87 | 1,212.43 | 5,745.79 | 4,684.66 | 6,761.75 |
| | Total Expenses (a to f) | 8,387.16 | 7,521.77 | 9,398.44 | 23,131.27 | 27,143.87 | 36,583.32 |
| 3 | Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2) | 484.04 | 472.57 | 335.16 | 1,387.89 | (507.92) | 276.15 |
| 4 | Other Income | 13.09 | 13.59 | 0.19 | 28.70 | 5.04 | 9.80 |
| 5 | Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4) | 497.13 | 486.16 | 335.35 | 1,416.59 | (502.88) | 285.95 |
| 6 | Finance costs (net) | 348.86 | 366.56 | 330.95 | 1,000.25 | 996.62 | 1,391.69 |
| 7 | Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6) | 148.27 | 119.60 | 4.40 | 326.34 | (1,499.50) | (1,105.74) |
| 8 | Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 9 | Profit/(Loss) from ordinary activities before tax (7-8) | 148.27 | 119.60 | 4.40 | 326.34 | (1,499.50) | (1,105.74) |
| 10 | Tax Expenses | | | | | | |
| | (a) Current Tax | - | 1.00 | (10.61) | 1.00 | - | 19.15 |
| | (b) Deferred Tax | 8.00 | (150.00) | (35.00) | (352.00) | (240.00) | (220.00) |
| | Total Tax Expenses (a+b+c+d) | 8.00 | (149.00) | (45.61) | (351.00) | (240.00) | (200.85) |
| 11 | Net Profit(+)/Loss(-) from ordinary activities after tax (9-10) | 140.27 | 268.60 | 50.01 | 677.34 | (1,259.50) | (904.89) |
| 12 | Extraordinary Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 13 | Net Profit(+)/Loss (-) for the period(11-12) | 140.27 | 268.60 | 50.01 | 677.34 | (1,259.50) | (904.89) |
| 14 | Share of Profit / (Loss) of associates | | | | | | |
| 15 | Minority Interest | | | | | | |
| 16 | Net Profit / (Loss) after taxes, minority interest and share of profit / -(loss) of associates (13-14-15) | 140.27 | 268.60 | 50.01 | 677.34 | (1,259.50) | (904.89) |
| 17 | Other Comprehensive income not reclassified into Profit and loss account (Net of Taxes) | (13.99) | (14.00) | 3.12 | (41.98) | 9.36 | (55.97) |
| 18 | Total Comprehensive Income (16+17) | 126.28 | 254.60 | 53.13 | 635.36 | (1,250.14) | (960.86) |
| 18 | Paid-up Equity Share Capital (Face value of Rs 10/- per share) | 1,582.82 | 1,582.82 | 1,582.82 | 1,582.82 | 1,582.82 | 1,582.82 |
| 19 | Reserve excluding Revaluation Reverses as per balance sheet of previous accounting year | | | | | | 12,651.95 |
| 20 | Earnings Per Share (EPS) (of Rs 10/-each not annualised): | | | | | | |
| | (a) Basic | 0.89 | 1.70 | 0.32 | 4.28 | (7.96) | (5.72) |
| | (b) Diluted | 0.89 | 1.70 | 0.32 | 4.28 | (7.96) | (5.72) |



[Handwritten Signature]

MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Notes :

- 1 The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.
- 2 The above unaudited financial result have been review by the audit committee and approved by the board of directors at their meeting held on February 13, 2025. The statutory auditors have expressed an unmodified opinion on the results for the quarter and nine months period ended on 31st December 24. The review report has been filed with the stock exchange and available on the copany website
- 3 The Company's business activity falls within a single reportable Business Segment Viz. "Manufacturing of Bulk Drugs".

4 The figures for the quarter ended 31st December, 2024 are the balancing figures between the Unaudited figures in respect of Nine Months ended upto 31st December 2024 and the unaudited published figures for half year ended 30th September 2024 .

5 The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("First Transferor Company") and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("Second Transferor Company") with Mangalam Drugs and Organics Limited ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to approval of Hon'ble National Company Law Tribunal, the shareholders and creditors of each of the companies.

6 Other Expenses

(Rupees In Lakhs)

| Sr.No | Particulars | Quarter Ended | | | Nine Months Ended | | Year Ended |
|-------|----------------------------|---------------|------------|------------|-------------------|------------|------------|
| | | 31.12.2024 | 30.09.2024 | 31.12.2023 | 31.12.2024 | 31.12.2023 | 31.03.2024 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| 1 | Power & Fuel Expenses | 2,125.43 | 842.35 | 588.14 | 2,125.43 | 2,015.76 | 2,849.67 |
| 2 | Job work Charges | 750.57 | 282.46 | 80.36 | 750.57 | 80.36 | 390.24 |
| 3 | Pollution Control Expenses | 631.84 | 226.00 | 116.62 | 631.84 | 630.46 | 854.78 |

7 The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation.

On behalf of Board of Directors
For Mangalam Drugs and Organics Limited

Shri Govardhan M.Dhoot
Chairman and Managing Director
DIN:01240086

Place: Mumbai
Date: February 13, 2025





V. S. SOMANI & CO.
CHARTERED ACCOUNTANTS

UNIT NO.127, 1ST FLOOR,
PRABHADEVI UNIQUE INDUSTRIAL
PREMISES CO-OP SOCIETY LTD.,
TWIN TOWER LANE,
OFF. VEER SAVARKAR MARG,
PRABHADEVI, MUMBAI 400 025.
PHONE NO: 022 66624558
EMAIL ID: vidyadhar@cavssomani.com

Limited Review Report on Unaudited Consolidated Financial Results of Mangalam Drugs and Organics Limited for the Quarter ended on 31st December, 2024 and year to date results for the period from 1st April, 2024 to 31st December 2024 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021 as amended.

To the Board of Directors,
Mangalam Drugs and Organics Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Mangalam Drugs and Organics Limited** (hereinafter referred to as "the Parent"), its subsidiary (the Parent and its subsidiary together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its subsidiary for the quarter ended 31st December 2024 and year to date results for the period from 1st April 2024 to 31st December 2024 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021.
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we




do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The statement includes the results of the Mangalam Laboratories Private Limited a subsidiary.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of a subsidiary included in the Statement, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs 1.06 Lakhs, Total net Loss after tax and total comprehensive income (before consolidation adjustments) of Rs 11.59 Lakhs for the quarter ended 31st December, 2024 and as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

For V.S. SOMANI & Co.,
Chartered Accountants
Firm Registration No. 117589W


somaní

C.A. Vidyadhar Somani
Proprietor

Membership No. 102664

UDIN No. 25102664BMITCY6158



Place: Mumbai
Date: February 13, 2025


MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



| Sr.No | Particulars | Quarter Ended | | | Nine Months Ended | | (Rs. In Lakhs) |
|--------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|-----------------|-------------------|-------------------|-------------------|
| | | 31.12.2024 | 30.09.2024 | 31.12.2023 | 31.12.2024 | 31.12.2023 | Year Ended |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| A) Part-1 Consolidated Statement of Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2024 | | | | | | | |
| 1 | Income from Operations | | | | | | |
| | (a) Net Sales and Services from Operations | 8,855.29 | 7,975.17 | 9,704.59 | 24,479.87 | 26,541.58 | 36,735.36 |
| | (b) Other Operating Income | 15.91 | 19.17 | 29.00 | 39.29 | 94.37 | 124.12 |
| | Total Income from Operations (net) (a+b) | 8,871.20 | 7,994.34 | 9,733.59 | 24,519.16 | 26,635.95 | 36,859.48 |
| 2 | Expenses | | | | | | |
| | (a) Cost of Materials Consumed | 4,486.12 | 4,340.21 | 4,664.80 | 12,879.77 | 17,320.54 | 22,475.54 |
| | (b) Purchase of Stock in trade | 371.01 | 234.89 | 198.90 | 1,214.08 | 263.33 | 1,065.35 |
| | (c) Changes in Inventories of, Finished Goods, and Work In Progress and Stock-in-trade | 234.93 | (508.72) | 2,062.81 | (893.59) | 1,001.61 | 910.33 |
| | (d) Employee Benefits Expenses | 1,033.75 | 1,017.77 | 897.12 | 3,008.37 | 2,796.48 | 3,907.13 |
| | (e) Depreciation and amortization expenses | 404.99 | 397.49 | 362.85 | 1,190.26 | 1,078.65 | 1,465.08 |
| | (f) Other Expenses (refer to note no B) | 1,867.57 | 2,039.74 | 1,212.17 | 5,744.09 | 4683.94 | 6,761.47 |
| | Total Expenses (a to f) | 8,399.27 | 7,521.38 | 9,398.65 | 23,143.00 | 27,144.55 | 36,584.90 |
| 3 | Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2) | 471.93 | 472.96 | 334.94 | 1,376.16 | (508.60) | 274.58 |
| 4 | Other Income | 13.61 | 13.59 | 0.19 | 29.22 | 5.04 | 9.80 |
| 5 | Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4) | 485.54 | 486.55 | 335.13 | 1,405.38 | (503.56) | 284.38 |
| 6 | Finance costs (net) | 348.86 | 366.56 | 330.95 | 1,090.25 | 996.62 | 1,391.70 |
| 7 | Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6) | 136.68 | 119.99 | 4.18 | 315.13 | (1,500.18) | (1,107.32) |
| 8 | Exceptional items | - | - | - | - | - | - |
| 9 | Profit/(Loss) from ordinary activities before tax (7-8) | 136.68 | 119.99 | 4.18 | 315.13 | (1,500.18) | (1,107.32) |
| 10 | Tax Expenses | | | | | | |
| | Current Tax | - | 1.00 | - | 1.00 | - | 19.85 |
| | Deferred Tax | 8.00 | (150.00) | (45.61) | (352.00) | (240.00) | (220.00) |
| | Total Tax Expenses (a+b) | 8.00 | (149.00) | (45.61) | (351.00) | (240.00) | (200.15) |
| 11 | Net Profit(+)/Loss(-) from ordinary activities after tax (9-10) | 128.68 | 268.99 | 49.79 | 666.13 | (1,260.18) | (907.17) |
| 12 | Extraordinary Items | - | - | - | - | - | - |
| 13 | Net Profit(+)/Loss (-) for the period(11-12) | 128.68 | 268.99 | 49.79 | 666.13 | (1,260.18) | (907.17) |
| 14 | Share of Profit / (Loss) of associates | - | - | - | - | - | - |
| 15 | Minority Interest | - | - | - | - | - | - |
| 16 | Net Profit / (Loss) after taxes, minority interest and share of profit / -(loss) of associates (13-14-15) | 128.68 | 268.99 | 49.79 | 666.13 | (1,260.18) | (907.17) |
| 17 | Other Comprehensive income not reclassified into Profit and loss account (Net of Taxes) | (13.99) | 694.12 | 3.12 | 666.14 | 9.36 | (55.97) |
| | Total Comprehensive Income (16+17) | 114.69 | 963.11 | 52.91 | 1,332.27 | (1,250.82) | (963.14) |
| 18 | Paid-up Equity Share Capital (Face value of Rs 10/- per share) | 1,582.82 | 1,582.82 | 1,582.82 | 1,582.82 | 1,582.82 | 1,582.82 |
| 19 | Reserve excluding Revaluation Reverses as per balance sheet of previous accounting year | - | - | - | - | - | 11,996.48 |
| 20 | Earnings Per Share (EPS) (of Rs 10/-each not annualised): | | | | | | |
| | (a) Basic | 0.81 | 1.70 | 0.31 | 4.21 | (7.96) | (5.73) |
| | (b) Diluted | 0.81 | 1.70 | 0.31 | 4.21 | (7.96) | (5.73) |



MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Notes :

- 1 The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.
- 2 The above unaudited financial result have been review by the audit committee and approved by the board of directors at their meeting held on February 13, 2025.The statutory auditors have expressed an unmodified opinion on the results for the quarter and nine months period ended on 31st December 24.The review report has been filed with the stock exchange and available on the copany website
- 3 The Company's business activity falls within a single reportable Business Segment Viz. "Manufacturing of Bulk Drugs".
- 4 The figures for the quarter ended 31st December, 2024 are the balancing figures between the Unaudited figures in respect of Nine Months ended upto 31st December 2024 and the unaudited published figures for half year ended 30th September 2024 .
- 5 Consolidated results includes results of Mangalam Laboratories Private Limited ,subsidiary for the purpose of Consolidated results.
- 6 As on september 30,2023 the Company has acquired 3010 Equity shares of Mangalam Laboratories Private Limited of Rs. 100 each. Mangalam Laboratories Private Limited became a wholly owned subsidiary of the Company .The wholly owned subsidiary is not a material subsidiary of the company on acquisition.
- 7 The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("First Transferor Company") and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("Second Transferor Company") with Mangalam Drugs and Organics Limited ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to approval of Hon'ble National Company Law Tribunal, the shareholders and creditors of each of the companies.

8 Other Expenses

(Rupees In Lakhs)


| Sr.No | Particulars | Quarter Ended | | | Nine Months Ended | | Year Ended |
|-------|----------------------------|---------------|------------|------------|-------------------|------------|------------|
| | | 31.12.2024 | 30.09.2024 | 31.12.2023 | 31.12.2024 | 31.12.2023 | 31.03.2024 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| 1 | Power & Fuel Expenses | 2,125.43 | 842.35 | 588.14 | 2,125.43 | 2,015.76 | 2,849.67 |
| 2 | Job work Charges | 750.57 | 282.46 | 80.36 | 750.57 | 80.36 | 390.24 |
| 3 | Pollution Control Expenses | 631.84 | 226.00 | 116.62 | 631.84 | 630.46 | 854.78 |

9)

Mangalam Laboratories Private Limited a wholly owned subsidiary Co. has revalued its land and building based on the valuation reoport received from the registered valuer as on 22 Aug, 2024. Consequtly , the above depreciation included depreication on revalued land and building for the quarter and nine month ended December 31st , 2024 that is amount of Rs.13.43 Lakhs

10 The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation.

On behalf of Board of Directors
For Mangalam Drugs and Organics Limited


Shri Govardhan M. Dhoot
Chairman and Managing Director
DIN:01240086

Place: Mumbai
Date: February 13 ,2025

